Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vestas partners with Pan American Energy to build a 423 MW wind park in Brazil

News release from Vestas Latin AmericaSão Paulo, 5 May 2022 Pan American Energy Energias Renováveis has signed an agreement with Vestas for the supply and installation of 94 V150-4.5 MW wind turbines for the Novo Horizonte wind park in the state of Bahia, Brazil. “Vestas is pleased to further grow the partnership with Pan American Energy and support their expansion in Latin America with this project that starts their renewables operation in Brazil”, says Eduardo Ricotta, President of Vestas Latin America. “This agreement shows Pan American Energy’s commitment to Brazil and its

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release May 5, 2022 at 10:05 a.m. Nokian Tyres has received an announcement from Société Générale SA (SG SA) on May 4, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement Société Générale SA’s total holding in Nokian Tyres shares exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on May 3, 2022. The holdings of Société Générale SA in Nokian Tyres amounted to 7,094,641 shares, corresponding to 5.11% of Nokian Tyres’ shares and voting rights.

AxFlow Ireland expands fluid handling solution offering

AxFlow Ireland, part of Axel Johnson International’s business group Fluid Handling Solutions, AxFlow, acquires Fin Maintenance Ltd. and Flow Technology Services Ltd. The two companies are leading experts in industrial maintenance, engineering services, and flow control to customers in the water, wastewater, energy, and manufacturing industries.“Back in 2019, AxFlow Ireland embarked on the journey of expanding our product portfolio and service offering. The recent acquisition of Fin Maintenance and Flow Technology Services is another important step in this direction”, says Stuart Flood,

Dystopian drama ‘The Fortress’ is Viaplay’s next Norwegian Original

· Ambitious eight-part series stars Tobias Santelmann (‘Exit’) and all-star Nordic and international cast · ‘The Fortress’ directed by Cecilie Mosli (‘Mammon’; ‘Grey’s Anatomy’) and Mikkel Brænne Sandemose (‘State of Happiness’) · Viaplay set to premiere at least 70 Originals in 2022 The latest Viaplay Original from Norway is ‘The Fortress’, an ambitious dystopian drama that depicts the fateful consequences of Norway’s decision to isolate itself and its citizens from the rest of the world. Tobias Santelmann (‘Exit’; ‘Kon-Tiki’), Selome Emnetu (‘Luka and the Magical Theater’) and UK

Interim Report Q1 2022 - Ayima Group AB

- Total Revenue amounted to 36.6 MSEK (36.8), a decrease of >1% from the previous year - Gross Profit increased by 5% to 21.6 MSEK (20.5) - EBITDA was 2.5 MSEK (5.1), a 52% decrease from the previous year - Net Profit after tax for the period was -0.6 MSEK (5.3) - Total Comprehensive Income was 0.2 MSEK (10.2) - Earnings per share (EPS) was 0.02 (1.38) The full report is available to be downloaded at https://www.ayimagroup.com/financial-results //

Denmark Becomes 15[th] Carl-Gustaf M4 Customer

Saab has received an order from the Danish Ministry of Defence Acquisition and Logistics Organisation (DALO) for the multi-role, man-portable Carl-Gustaf® M4 weapon, making Denmark the 15[th] customer for the M4 version. Deliveries will take place in 2022.The recoilless Carl-Gustaf M4 weapon increases tactical flexibility. Built to satisfy future requirements, it is compatible with advanced fire control devices and prepared for specialised ammunition, putting advanced technology at forces’ fingertips. “We are ready to supply Denmark with Carl-Gustaf M4. The user-focused design of the

IMAE and Wyld Networks sign contract to deploy satellite IoT solution for wind turbines in Brazil

Wyld Networks today announce a partnership with IMAE to deploy its Wyld IoT sensor-to-satellite technology with IMAE’s wind turbine technology in the utility sector in Brazil. IMAE will pilot Wyld’s solution and sign a commercial agreement.IMAE is a Brazilian company, based in Sao Paolo, that have developed a wind turbine technology for micro generation, for deployment in for example in remote locations. They have been contracted to supply electricity to 3000 locations in Brazil using this technology. Wyld Connect will enable data collection and control for all these wind turbines in

Photocure ASA: Invitation to presentation of first quarter 2022 financial results

Oslo, Norway, 5 May 2022: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2022 financial results on Wednesday 11 May 2022 at 08:00 CET and invites investors, analysts and the media to a presentation at Hotel Continental, Oslo, Norway at 14:00 CET the same day.The investor presentation will also be streamed live and be hosted by Daniel Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45 CET. The quarterly report and presentation will be

LINK Mobility names large East Coast customer in the US

Oslo Norway, 5 May 2022: LINK Mobility (LINK) has won additional business on the East Coast with the large U.S. utility company AVANGRID through its U.S. subsidiary Message Broadcast. The win was included, unnamed, in the 4Q21 presentation on 10 February 2022. The agreement renews three subsidiary utilities (New York State Electric and Gas, Rochester Gas & Electric, and Central Maine Power) and onboards four additional East Coast utilities (Berkshire Gas Company, Connecticut Natural Gas, Southern Connecticut Gas, and United Illuminating Company). AVANGRID’S utility companies serve 3 million

Lipidor AB (publ) publishes interim report for first quarter 2022

STOCKHOLM, Sweden, 5 May 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period 1 January – 31 March 2022. The report is available on the company's website lipidor.se  and in the attached pdf.Summary of year-end report During the first quarter, the first patients were enrolled in a Phase III clinical trial with AKP02 cutaneous spray for mild to moderate psoriasis. The study will be carried out during the first half of 2022. The subsidiary Emollivet AB has launched COMBI -

LEAX Interim Financial Report Q1

Challenging and Exciting TimesSummary of the first quarter of 2022 · Net Sales amounted to SEK 436.8 million (471.2) · Adjusted EBITDA amounted to SEK 34.8 million (52.6) · Earnings before tax (EBT) decreased to SEK -8.4 million (15.9) · Cash flow from operations increased to SEK 13.9 million (-10.1) · Net income for the period decreased to SEK -7.3 million (11.8) · Earnings per share amounted to SEK -0.62 (0.88) Revenue in the first quarter of 2022 was down just over 7% versus Q1 2021, SEK 436.8 million (473.1) and was directly attributable to supply chain

Interim report January – March 2022

First quarter 2022• Net sales increased to SEK 3,779m (3,373) corresponding to organic sales growth of 6% (3).• Operating profit decreased to SEK 182m (196), corresponding to an operating margin of 4.8% (5.8).• Changes in exchange rates positively impacted operating profit by SEK 30m.• Profit after tax amounted to SEK 128m (132), corresponding to earnings per share before and after dilution of SEK 0.76 (0.78).• Operating cash flow amounted to SEK -420m (-69), of which -263m (-9) was related to investments in the new Nordic factory.• Superfront was acquired.• Adjusted segment

Interim Report 1 January–31 March 2022

We have put yet another turbulent quarter behind us following the reintroduction of restrictions at the end of last year, which were made even more stringent in the beginning of January. Consequently, the majority of our arenas had to postpone their seasonal opening, while the demand for tickets for upcoming periods declined. However, we are pleased to note that since being allowed to reopen all of our operations at the end of February, we have enjoyed good seat occupancy, especially for our major productions, and strong demand in our two event companies, while most of the other operations

Interim report, 1 January–31 March 2022

Stronger product tanker market · Total income Q1:SEK 124.1 (179.6) million  · EBITDA Q1:SEK 29.7 (–45.7) million  · Result before tax Q1:SEK –30.4 (–120.2) million  · Result per share after tax Q1:SEK –0.64 (–2.54) Events in the first quarter · Sale of two P-MAX vessels · P-MAX vessel Stena Polaris chartered out · Technical design study for possible container conversion launched · New long-term financial covenant terms Events after the end of the quarter · No significant events occurred after the end of the quarter. Key figures

Q1 2022: NORDEN WITH STRONG START TO THE YEAR

ANNOUNCEMENT NO. 111 - 5 MAY 2022 For the first quarter of 2022, NORDEN reports a profit of USD 117 million (Q1 2021: USD -15 million). NORDEN CEO, Jan Rindbo, comments: “Great Q1 result based on strong performances in both business units as we continue to capture value in the dry cargo market through vessel sales, profitable cover and by utilising regional market volatility. By shifting our market exposure from dry cargo to tankers, combined with excellent vessel positioning towards a much-improved tanker market in recent weeks, NORDEN expects a full-year result between USD 270-

3 new companies to present at the BioStock Life Science Spring Summit on June 8-9!

On June 8-9, it is finally time for BioStock Life Science Spring Summit 2022, where companies from a wide range of therapeutic areas will present their projects and innovations, in a packed program that also offers valuable insights from investment experts and industry profiles. Today, we reveal three new companies that will present at the Summit!The event will be broadcasted on the BioStock website and on our YouTube channel. You can also access the event through our social media platforms. Today we reveal three new companies that will present at the BioStock Life Science Spring Summit

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital5 May 2022 at 9.15 EET Nordea Bank Abp (“Nordea”) has today cancelled 49,243,777 treasury shares, which were held for capital optimisation purposes and acquired through share buy-backs, in line with the decision by the Board of Directors. The cancellation of the treasury shares has been registered with the Finnish Trade Register on 5 May 2022. After the cancellation, the total number of shares in Nordea is 3,789,514,793 and the total number of votes attached to the shares is 3,789,514,793. Nordea

Change in Pihlajalinna Plc’s Management Team

Pihlajalinna Plc Stock exchange release  5 May 2022 at 9.10 a.m.   Change in Pihlajalinna Plc’s Management Team   Pihlajalinna is planning the renewal of its operating structure and a transition to an organisational structure based on business activities. The renewal of the operating structure would also lead to a change in Pihlajalinna’s segment reporting. Going forward, the operating segments would be the company’s two business segments: Public Services, and Private Clinic and Hospital Services.Pihlajalinna Group has appointed Eetu Salunen, Licentiate of Medicine and Master

Invitation to presentation of Interim Report January 1 – March 31, 2022

Mekonomen’s Interim Report for the first quarter 2022 will be published on Wednesday 11 May at 07:30 a.m CEST. A webcast/telephone conference will be held on the same day at 09:00 a.m CEST in English. Mekonomen's President and CEO Pehr Oscarson and CFO Åsa Källenius will present the results and respond to questions at the English speaking conference. The presentation material will be available from 8:00 a.m CEST on 11 May, at www.mekonomen.com under the heading Investors/IR Presentations.  

Enhertu approved in US for 2L HER2+ breast cancer

05 May 2022 07:10 BST Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or

Interim Report First Quarter 2022

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2022 – 31.03.2022. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:When we look back on Q1 2022 it was gratifying to see the hard work of 2021 successfully completed: We had a medical cannabis oil product approved for Denmark, we entered the UK market with three approved

BioStock: Sprint Bioscience launches NIMA at BIO International

It has been a little more than six months since Huddinge-based Sprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16. BioStock contacted Martin Andersson, CSO at Sprint Bioscience, to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-launches-nima-at-bio-international/This is a press release from BioStock - Connecting

Farxiga HFpEF Phase III trial met primary endpoint

5 May 2022 07:05 BST Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Results from the DELIVER and DAPA-HF Phase III trials demonstrate Farxiga's efficacy in heart failure regardless of ejection fraction High-level results from the DELIVER Phase III trial showed AstraZeneca's Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

Ultomiris NMOSD Ph. III trial met primary endpoint

5 May 2022 07:00 BST Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder Zero adjudicated relapses observed among Ultomiris patients over a median treatment duration of 73 weeks   Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the

There are no items matching the current filter
There are no more items matching the current filter
Back to top